Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
INVO Fertility ( (IVF) ) just unveiled an announcement.
INVO Fertility, Inc. has signed a definitive agreement to acquire the non-clinical assets of Family Beginnings, a well-regarded fertility clinic in Indianapolis, Indiana, for $750,000. The acquisition is expected to close by February 27, 2026, subject to conditions such as regulatory approvals. This deal reflects INVO’s strategic plan to grow its network of fertility centers across the U.S. and enhance its offerings by integrating Family Beginnings’ well-established services, which generated $1.2 million in revenue over the past year. Dr. James Donahue, the clinic’s owner and medical director, will continue leading the clinic under a three-year contract. The acquisition aligns with INVO’s mission to improve access to fertility care and could strengthen its market position as a leading provider of innovative ART solutions.
The most recent analyst rating on (IVF) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on INVO Fertility stock, see the IVF Stock Forecast page.
Spark’s Take on IVF Stock
According to Spark, TipRanks’ AI Analyst, IVF is a Neutral.
INVO Fertility’s overall stock score is primarily impacted by its weak financial performance and technical analysis, both indicating significant challenges. However, recent corporate events provide a positive outlook for potential strategic improvements.
To see Spark’s full report on IVF stock, click here.
More about INVO Fertility
INVO Fertility, Inc. is a healthcare services company dedicated to expanding access to assisted reproductive technologies (ART). The company specializes in building, acquiring, and operating fertility clinics, with a focus on intravaginal culture (IVC) enabled by its proprietary INVOcell device. INVO offers cost-effective ART treatments, including in vitro fertilization (IVF) and other related services, with a goal to make advanced fertility care more accessible and affordable. The company operates multiple fertility centers in the United States and distributes its INVOcell device to third-party clinics.
Average Trading Volume: 923,558
Technical Sentiment Signal: Strong Sell
Current Market Cap: $2.82M
Learn more about IVF stock on TipRanks’ Stock Analysis page.